News | April 30, 2026
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The Danish biotech company confirmed the global study will begin in the second half of 2026
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Company to highlight science-backed actives, nature-powered ingredients, and its new “Natural by Barentz” private label platform in Barcelona
Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Subscribe To Our Newsletter & Stay Updated
